相关实验视频

Updated: Sep 12, 2025

The MPLEx Protocol for Multi-omic Analyses of Soil Samples

The MPLEx Protocol for Multi-omic Analyses of Soil Samples

Published on: May 30, 2018

通过使用多omics在人类中研究dpeptidyl peptidase-1抑制的影响

Merete B Long¹, Amy Gilmour¹, Rebecca C Hull²

¹Division of Respiratory Medicine and Gastroenterology, University of Dundee, Dundee, United Kingdom.

The Journal of allergy and clinical immunology

|August 8, 2025

概括

在严重的COVID-19患者中,brensocatib显著改变了中性粒细胞蛋白的二乙酶-1 (DPP-1) 抑制. 阿祖罗西丁-1受到严重影响,突出了其作为DPP-1抑制剂疗效生物标志物的潜力.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
蛋白质组学是指蛋白质组学.

背景情况:

双基酶-1 (DPP-1/Cathepsin C) 对于激活中性粒细胞血清蛋白酶至关重要.
布伦索卡提布是一种口服的DPP-1抑制剂,用于支气管切除,并降低蛋白酶活性.
DPP-1抑制的更广泛的免疫效应在很大程度上仍未得到研究.

研究的目的:

研究DPP-1抑制对免疫反应的影响.
在严重的COVID-19患者中,分析与brensocatib治疗相关的免疫变化.
为了对STOP-COVID19试验数据进行二次分析.

主要方法:

随机的安慰剂对照STOP-COVID19试验的二次分析,涉及住院COVID-19患者的布伦索卡提布.
在基线和8,15,29天收集血液样本进行分析.
使用了外周血液中性粒细胞质谱,功能测试,血清细胞因子分析,全血mRNAseq和中性粒细胞相关标记物测量.

主要成果:

中性粒细胞蛋白组学揭示了15种蛋白质的显著变化,包括减少甲素G和亚苏罗丁-1.
血清亚苏罗丁-1水平显著降低,而弹性酶和蛋白酶3水平没有.
观察到蛋白酶可分离C5aR1/CD88的中性粒细胞表面表达增加;没有发现NET,细胞化,细胞比例或基因表达的差异.

结论:

在COVID-19患者中,布伦索卡提布治疗显著改变了中性粒细胞蛋白质概况.
阿祖罗西丁-1受到严重影响,被确定为DPP-1的关键目标.
阿祖罗西丁-1可以作为监测DPP-1抑制剂治疗疗效的敏感生物标志物.

关键词:

亚祖罗西丁-1-1的存在燃烧器是一种可动剂.卡特赫普辛C C的时间在DPP-1中,双基化酶-1的二基化酶-1是什么?肝素结合蛋白是一种肝素结合蛋白.炎症炎症是一种炎症.多个omics的多个omics.作为一个中性粒细胞.蛋白质组学是指蛋白质组学.

更多相关视频

Author Spotlight: Multi-Layered Approach to Understand Postnatal Functions of Pancreatic Islets in Non-Human Primates

Author Spotlight: Multi-Layered Approach to Understand Postnatal Functions of Pancreatic Islets in Non-Human Primates

Published on: November 8, 2024

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...